In a randomized trial, oral linezolid (600 mg once daily) vs. benzathine penicillin G did not meet the noninferiority margin.
Alternative treatments for syphilis, preferably with orally administered medications, are urgently needed. Linezolid has bactericidal properties in vitro against Treponema pallidum. Investigators in Catalonia randomized persons with early syphilis (primary, secondary, or early latent) to receive oral linezolid (600 mg once daily for 5 days) or intramuscular benzathine penicillin G (2.4 mIU; standard of care). Treatment response was defined as clinical improvement, a fourfold decline in rapid plasma reagin titer, and absence of relapse.
The trial was stopped early for futility after 59 participants (all men) had been randomized. In the penicillin arm, 100% of 28 participants responded as compared with 19 of 27 (70%) in the linezolid arm. Alth…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)